2023 World Conference on Lung Cancer (Posters)-EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer

EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer - PDF(Abstract)

Pdf Summary

This study aimed to determine real-world outcomes in patients with third-line extensive stage small cell lung cancer (ES SCLC). The study analyzed electronic medical records of ES SCLC patients who received three lines of therapy between July 2012 and June 2022. The outcomes measured included duration of response (DOR), overall survival (OS), progression-free survival (PFS), and related clinical outcomes.<br /><br />The study included 113 patients with ES SCLC, with a median age of 58 years. At the initiation of the third-line therapy, 66% had an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, indicating better overall function, while 33% had an ECOG score of 2, indicating worse function. The results showed that 19% of patients had physician-reported tumor shrinkage, 2% had a complete response, and 13% had stable disease.<br /><br />The median DOR was 2.8 months, total duration of benefit response was 2.5 months, OS was 5.8 months, and PFS was 2.4 months in the third-line setting. Patients with an ECOG score of 0 or 1 had a significantly longer time to next treatment or death compared to those with an ECOG score of 2.<br /><br />The findings of this real-world study were similar to those reported in clinical trial settings, indicating limited clinical benefits with current therapies in patients with third-line ES SCLC. Patients with better ECOG scores demonstrated a longer time to next treatment or death, suggesting their ability to receive subsequent lines of therapy.<br /><br />Overall, more research is needed to identify novel therapies that can improve response and disease progression in patients with ES SCLC.

Asset Subtitle

Jair Bar

Meta Tag

Speaker Jair Bar

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

extensive stage small cell lung cancer

real-world outcomes

electronic medical records

duration of response

overall survival

progression-free survival

Eastern Cooperative Oncology Group

physician-reported tumor shrinkage

complete response

stable disease